NCT04837833Active, not recruiting
An Ultrasound Imaging Technique to Measure Tumors in People With Pancreatic Ductal Adenocarcinoma (PDAC) or Gastrointestinal (GI) Adenocarcinoma
Machine Learning Approach to Sonographic Assessment of Tumor Volumes for Response Assessment in Patients With Pancreas or Gastrointestinal Adenocarcinoma: A Pilot Study
Source: ClinicalTrials.gov · Last updated 27 Apr 2026
Brief summary (registry, in English)
The purpose of this study is to see if ultrasound images that are analyzed by a special computer program can be used to measure the size of PDAC tumors in the liver as accurately as CT scans that involve contrast material (also called contrast-enhanced CT scans). All participants in this study will have pancreatic ductal adenocarcinoma (PDAC) that has spread (metastasized) to the liver, and all participants will be scheduled for a routine CT scan that will measure their cancer.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 19 (actual)
- First submitted
- 6 Apr 2021
- Start date
- 6 Apr 2021
- Primary completion date
- 6 Apr 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Pancreatic cancer
- NCT number
- NCT04837833
What you commit to
- Study type: Interventional
- Participants enrolled: 19
- From 6 Apr 2021 to the primary completion date, 6 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Inability to tolerate intravenous contrast medium
- All liver metastases ≤ 10 mm in maximal diameter on the contrast enhanced CT used for comparison to the planned research ultrasound
- Multiple confluent liver metastases or tumor burden \> 50% of the liver as estimated by a radiologist
Who the study is looking for
- Male and female patients, 18 years of age or older
- Confirmed diagnosis of PDAC or GI tract adenocarcinoma metastatic to liver
- Scheduled for imaging with contrast enhanced CT
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.